| 2006-07 |
Founded by Yuichi Suga (developer of Flexizyme technology and professor at the University of Tokyo) and Kichi Kubota (former chairman of the company), the company was established in Chiyoda-ku, Tokyo (the lab is located within the University of Tokyo Research Center for Advanced Science and Technology). |
| 2006-07 |
PeptiDream was founded in Tokyo, Japan |
| 2006-12 |
Obtained exclusive implementation and licensing rights with sublicensing to third parties centered on Flexizyme from the University of Tokyo. |
| 2006-12 |
Entered into a sub-licensable exclusive license agreement with the University of Tokyo on Flexizyme Technology |
| 2007-05 |
Obtained exclusive implementation and licensing rights with sublicensing to third parties for the basic patents related to Flexizyme development with the State University of New York. |
| 2007-05 |
Entered into a sub-licensable exclusive license agreement with the State University of New York on Flexizyme Technology |
| 2009-03 |
Relocated headquarters to Meguro-ku, Tokyo (within the University of Tokyo Research Center for Advanced Science and Technology). |
| 2009-03 |
Relocated corporate headquarters to RCAST (Research Center for Advanced Science and Technology, The University of Tokyo) |
| 2010-04 |
Relocated headquarters and laboratory functions to Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL). |
| 2010-04 |
Relocated corporate headquarters and research laboratories to Komaba Reserch Campus, The University of Tokyo |
| 2010-10 |
Established the proprietary technology, the Peptide Discovery Platform System (PDPS). |
| 2010-10 |
Established its proprietary technology “Peptide Discovery Platform System (PDPS).” |
| 2013-06 |
Listed on the Tokyo Stock Exchange Mothers market. |
| 2013-06 |
Listed on the Tokyo Stock Exchange Mothers |
| 2015-12 |
Changed to the First Section of the Tokyo Stock Exchange. |
| 2015-12 |
Listed on the first section of the Tokyo Stock Exchange. |
| 2015-12 |
Changed to the First Section of the Tokyo Stock Exchange. |
| 2017-07 |
Relocated headquarters and research institute to a new building within the international strategy base "Kings Sky Front" in Tonemachi, Kawasaki City, Kanagawa Prefecture, from Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL). |
| 2017-07 |
Relocated corporate headquarters to Tonomachi, Kawasaki City. |
| 2017-07 |
Relocated headquarters and research institute to a new building within the international strategy base "Kings Sky Front" in Tonemachi, Kawasaki City, Kanagawa Prefecture, from Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL). |
| 2017-09 |
Patrick Reid, who as a founding member established the PDPS core technology and oversaw various research and development programs with pharmaceutical companies as CSO (Chief Science Officer), became the president and CEO. |
| 2017-09 |
Founded PeptiStar Inc., a CDMO (Contract Development and Manufacturing Organization) for research, development, manufacturing, and sales of special peptide raw materials in a joint venture with Shionogi & Co., Ltd. and Sekisui Chemical Co., Ltd. |
| 2017-09 |
Patrick C. Reid was appointed as President and CEO |
| 2017-09 |
PeptiStar Inc. was founded through a joint venture agreement between PeptiDream Inc., Shionogi & Co., Ltd. and Sekisui Chemical Co., Ltd. |
| 2020-04 |
Founded PeptiGrowth Inc., a joint venture with Mitsubishi Corporation to develop, manufacture, and sell peptides that replace growth factors, a key component of cell culture media. |
| 2020-04 |
PeptiGrowth Inc. was founded through a joint venture agreement between PeptiDream Inc. and Mitsubishi Corporation. |
| 2020-11 |
Founded PeptiAID Inc., a joint venture with Fujitsu Ltd., Mizuho Capital Co., Ltd., Takenaka Corporation, and Kishida Chemical Co., Ltd. to develop treatments for COVID-19. |
| 2020-11 |
PeptiAID Inc. was founded through a joint venture agreement between PeptiDream Inc., Fujitsu Limited, Mizuho Capital Co., Ltd., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD. |
| 2022-03 |
Made PDR Pharma Inc., a new company that succeeded the radiopharmaceutical business of Fujifilm Toyama Chemical through a spin-off, a subsidiary. |
| 2022-03 |
Fully acquire a newly established company, PDRadiopharma Inc. that succeeds the radiopharmaceutical business of Fujifilm Toyama Chemical. |
| 2022-04 |
Changed to the Prime Market of the Tokyo Stock Exchange. |
| 2022-04 |
Changed to the Prime Market of the Tokyo Stock Exchange |
